Ironwood Pharmaceuticals, Inc. - (IRWD) News
Filter IRWD News Items
IRWD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IRWD News Highlights
- For IRWD, its 30 day story count is now at 12.
- Over the past 18 days, the trend for IRWD's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- VECT, AG and DRUG are the most mentioned tickers in articles about IRWD.
Latest IRWD News From Around the Web
Below are the latest news stories about IRONWOOD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IRWD as an investment opportunity.
Why Ironwood Pharmaceuticals Stock Bumped Higher TodayIronwood Pharmaceuticals (NASDAQ: IRWD) is choosing to go the acquisition route to grow its business. On Monday, the company announced it has agreed to acquire clinical-stage biotech VectivBio Holding (NASDAQ: VECT). Investors were clearly warm to that move, as they subsequently traded up Ironwood stock by almost 4% on the day. |
VectivBio Stock Catapults 39% After Ironwood Agrees To Buy It For $1 BillionIronwood Pharmaceuticals said Monday it will buy VectivBio for $1 billion. The deal sent VECT stock flying, while IRWD stock reversed higher. |
Ironwood spends $1B to acquire Swiss biotechIronwood Pharmaceuticals Inc. is beefing up its gastrointestinal drug portfolio by buying a Swiss biotech called VectivBio Holding AG. |
Why Shares of VectivBio Holding Are Up TodayShares of VectivBio Holdings (NASDAQ: VECT) were up more than 35% Monday morning after the clinical-stage biotech company received a buyout offer from Ironwood Pharmaceuticals (NASDAQ: IRWD). Ironwood's shares were down a little more than 2% on Monday morning. Ironwood, which specializes in gastrointestinal therapies, said it was acquiring VectivBio in a $1 billion all-cash deal, offering $17 a share for VectivBio, a 42% premium of what the stock closed at on Friday. |
Ironwood Pharmaceuticals to Buy VectivBio in $1 Billion Deal. The Sector Is Hot for M&A.The drugmaker is paying $17 a share for the Swiss biotech company. The move adds to the $71 billion worth of deals announced in the healthcare and life sciences space in the first quarter. |
Ironwood bulks up on digestive therapies with $1.15 billion VectivBio buy(Reuters) -Ironwood Pharmaceuticals Inc said on Monday it would buy Switzerland-based drug developer VectivBio Holding AG for $1.15 billion, adding a promising treatment for digestive disorders to its portfolio. Ironwood has offered $17 per share for VectivBio, a premium of about 43% to the stock's last close. VectivBio's shares were at $16.21 in morning trade, while Ironwood's stock fell 4.5% to $10. |
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal DiseasesBOSTON & BASEL, Switzerland, May 22, 2023--Ironwood Pharmaceuticals, Inc. ("Ironwood") (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG ("VectivBio") (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that they have entered into a definitive agreement for Ironwood to acquire VectivBio for $17.00 per share in an all-cash transaction with an estimated aggregat |
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences ConferenceBOSTON, May 09, 2023--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 1:30 p.m. ET at the New York Hilton Midtown. |
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023BOSTON, May 08, 2023--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented findings during the 2023 Digestive Disease Week® (DDW) meeting from a Phase III clinical trial on the potential of linaclotide for children and adolescents ages 6-17 years-old with functional constipation. Ironwood had previously announced topline data from this study in September 2022. |
Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume UpIronwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand. |